FDA recommends Ketek warning label: WSJ
Posted on: Friday, 19 May 2006, 05:33 CDT
NEW YORK/PARIS (Reuters) - The U.S. Food and Drug Administration reviewers have linked Sanofi-Aventis SA's antibiotic Ketek to 12 cases of liver failure, including four deaths, and is now recommending the company put a warning label on the drug, the Wall Street Journal said on Friday.
The paper said the cases were reported in a May 16 memo which it has seen from the FDA's Division of Drug Risk Evaluation.
The company said it "continues to believe that Ketek is safe and effective when used as directed," according to a company statement issued to the Journal.
No one could be immediately reached for comment at Sanofi in Paris, where Sanofi shares were down 1.4 percent at 72.65 euros at 0849 GMT, making them the third biggest loser in the CAC-40 index of leading French shares.
U.S. lawmakers have questioned the FDA's 2004 approval of the drug amid charges of faulty data from one of the trials.
Ketek, which was approved to treat respiratory infections, drew renewed scrutiny in January when researchers reported that three patients using the drug developed severe liver damage and one died.
The FDA rejected the drug in 2001 and 2003, asking for more safety information.
A U.S. representative for Sanofi-Aventis could not immediately be reached for further comment.
Source: REUTERS
Related Articles
- Sanofi-Aventis: FDA Restricts Ketek's Commercial Opportunity
- DOR BioPharma Files New Drug Application With FDA to Market orBec for GI GVHD
- Almost All New Drug Approvals Receive FDA Requests for Post-Marketing Studies
- Canada: may be tie between Sanofi's Ketek, liver harm
- Sanofi's Ketek antibiotic safety profile unchanged
- Genta Files New Drug Application for FDA Approval of Genasense(R) Plus Chemotherapy for Patients With Advanced or Refractory Chronic Lymphocytic Leukemia
- Osiris Receives Orphan Drug Status From FDA for Lead Stem Cell Drug
- Boca Drug Firm Gets FDA Approval for Pill
- Spectrum Pharmaceuticals Announces Filing of an ANDA for an Injectable Anticancer Drug With the FDA
- Bothell-Based Natural Remedy Company Receives Investigational New Drug Number From FDA
 |
 |
User Comments (0)
RSS Feeds